Seroatlas · Human Serome Atlas

EAF2

ELL-associated factor 2

Also known as: BM040, EAF2_HUMAN, TRAITS, U19

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q96CJ1
Gene: EAF2
Ensembl: ENSG00000145088
Chromosome: 3
Canonical length: 260 aa
Protein class: Predicted intracellular proteins

OverviewNCBI Gene

Enables transcription elongation factor activity. Involved in positive regulation of transcription by RNA polymerase II and regulation of transcription elongation by RNA polymerase II. Part of transcription elongation factor complex. Biomarker of prostate cancer. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

260 residues, UniProt reviewed canonical sequence.

>Q96CJ1|EAF2
     1  MNSAAGFSHL DRRERVLKLG ESFEKQPRCA FHTVRYDFKP ASIDTSSEGY LEVGEGEQVT
    61  ITLPNIEGST PPVTVFKGSK KPYLKECILI INHDTGECRL EKLSSNITVK KTRVEGSSKI
   121  QYRKEQQQQQ MWNSARTPNL VKHSPSEDKM SPASPIDDIE RELKAEASLM DQMSSCDSSS
   181  DSKSSSSSSS EDSSSDSEDE DCKSSTSDTG NCVSGHPTMT QYRIPDIDAS HNRFRDNSGL
   241  LMNTLRNDLQ LSESGSDSDD

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against EAF2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.54
Highest tissue expression: 68 nTPM

Expression across tissuesHPA

Tissue

bone marrow: 68 nTPM
lymph node: 50 nTPM
tonsil: 41 nTPM
kidney: 28 nTPM
prostate: 20 nTPM
appendix: 18 nTPM

Single-cell type

plasma cells: 366 nCPM
neutrophil progenitors: 216 nCPM
megakaryocytes: 185 nCPM
prostatic glandular cells: 179 nCPM
monocyte progenitors: 131 nCPM
b-cells: 122 nCPM

Immune cell

memory B-cell: 105 nTPM
naive B-cell: 98 nTPM
non-classical monocyte: 55 nTPM
eosinophil: 43 nTPM
intermediate monocyte: 41 nTPM
plasmacytoid DC: 31 nTPM

Brain region

thalamus: 6.5 nTPM
hypothalamus: 5.9 nTPM
cerebral cortex: 5.8 nTPM
pons: 5.4 nTPM
midbrain: 5.2 nTPM
amygdala: 5.1 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.45
gnomAD pLI: 0
gnomAD missense Z: 0.25
DepMap mean gene effect: -0.01
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

transcription elongation factor activity

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of EAF2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads EAF2 as an antibody target. Whether an autoantibody or antibody against EAF2 could matter depends on whether native EAF2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

EAF2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label EAF2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...